Milestone Pharmaceuticals (MIST) Competitors $1.70 -0.01 (-0.58%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, NGNE, CADL, and LRMRShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Neurogene (NGNE), Candel Therapeutics (CADL), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Candel Therapeutics Larimar Therapeutics Milestone Pharmaceuticals (NASDAQ:MIST) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Is MIST or ABEO more profitable? Abeona Therapeutics' return on equity of 89.05% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -1,672.29% -83.09% Abeona Therapeutics N/A 89.05%45.64% Which has stronger earnings and valuation, MIST or ABEO? Milestone Pharmaceuticals has higher earnings, but lower revenue than Abeona Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone PharmaceuticalsN/AN/A-$41.52M-$0.84-2.02Abeona Therapeutics$3.50M105.93-$63.73M$0.7010.33 Do institutionals & insiders believe in MIST or ABEO? 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, MIST or ABEO? Milestone Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Does the media prefer MIST or ABEO? In the previous week, Abeona Therapeutics had 21 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 24 mentions for Abeona Therapeutics and 3 mentions for Milestone Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.49 beat Milestone Pharmaceuticals' score of -0.39 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend MIST or ABEO? Milestone Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 194.12%. Abeona Therapeutics has a consensus price target of $19.50, indicating a potential upside of 169.71%. Given Milestone Pharmaceuticals' higher possible upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Abeona Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAbeona Therapeutics beats Milestone Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.42M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-2.0220.8831.1026.05Price / SalesN/A342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book-8.108.129.536.61Net Income-$41.52M-$54.72M$3.26B$265.56M7 Day PerformanceN/A2.63%2.10%1.97%1 Month Performance6.25%2.78%2.81%-0.36%1 Year Performance15.65%11.01%30.56%19.03% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.3665 of 5 stars$1.70-0.6%$5.00+194.1%+18.1%$91.42MN/A-2.0230ABEOAbeona Therapeutics4.4435 of 5 stars$6.28+0.3%$19.25+206.5%+41.2%$320.24M$3.50M-4.9490News CoverageAnalyst RevisionOLMAOlema Pharmaceuticals1.7657 of 5 stars$4.57-1.5%$24.50+436.1%-50.0%$317.48MN/A-2.2770ALDXAldeyra Therapeutics2.0925 of 5 stars$5.25-0.2%$9.50+81.0%+11.1%$315.05MN/A-6.1810AMRNAmarin0.2855 of 5 stars$14.94-0.3%$12.00-19.7%+29.9%$310.40M$228.61M-4.07360Positive NewsBNTCBenitec Biopharma1.3997 of 5 stars$11.90+0.8%$26.00+118.5%+44.3%$309.76M$80K-7.8820News CoverageRCKTRocket Pharmaceuticals4.8792 of 5 stars$2.92+2.1%$16.33+459.4%-80.3%$308.61MN/A-1.16240Analyst ForecastAnalyst RevisionINBXInhibrx Biosciences1.7142 of 5 stars$21.40+1.6%N/A+92.5%$304.86M$200K0.18166Analyst ForecastShort Interest ↓NGNENeurogene1.7297 of 5 stars$20.35-4.1%$46.17+126.9%-40.9%$302.64M$930K-4.6890CADLCandel Therapeutics2.5891 of 5 stars$6.21+3.2%$22.00+254.3%+12.1%$301.62M$120K-4.6360LRMRLarimar Therapeutics2.2329 of 5 stars$3.78+5.6%$18.50+389.4%-49.3%$296.35MN/A-2.5430 Related Companies and Tools Related Companies ABEO Alternatives OLMA Alternatives ALDX Alternatives AMRN Alternatives BNTC Alternatives RCKT Alternatives INBX Alternatives NGNE Alternatives CADL Alternatives LRMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access